INT323912

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.01
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 4
Disease Relevance 1.06
Pain Relevance 1.78

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (ARC) plasma membrane (ARC) cytoskeleton organization (ARC)
cytoplasm (ARC)
ARC (Homo sapiens)
Pain Link Frequency Relevance Heat
Etanercept 164 98.88 Very High Very High Very High
Infliximab 188 98.56 Very High Very High Very High
Arthritis 232 97.28 Very High Very High Very High
antagonist 196 96.60 Very High Very High Very High
spinal inflammation 200 80.16 Quite High
Adalimumab 160 50.00 Quite Low
rheumatoid arthritis 32 5.00 Very Low Very Low Very Low
spondylitis 28 5.00 Very Low Very Low Very Low
psoriasis 24 5.00 Very Low Very Low Very Low
visual analogue scale 16 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Seronegative Spondarthritis 216 97.28 Very High Very High Very High
Arthritis 8 81.20 Quite High
Low Back Pain 228 80.16 Quite High
Psoriasis 36 55.44 Quite High
Necrosis 16 50.00 Quite Low
Cancer 16 50.00 Quite Low
Infection 8 28.16 Quite Low
Hypersensitivity 8 15.84 Low Low
Disease 52 5.00 Very Low Very Low Very Low
Rheumatoid Arthritis 36 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
ACR50 and mPsARC responses were achieved by five and seven, respectively, of 13 patients with PsA with lack of response to prior TNF-antagonist treatment; by 10 and 17 of 27 patients with loss of response; and by five and seven of eight patients who were intolerant of prior anti-TNF therapy (observed data).
Regulation (responses) of mPsARC associated with antagonist and arthritis
1) Confidence 0.01 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911911 Disease Relevance 0.26 Pain Relevance 0.44
At week 12, the percentages of patients who achieved ACR50 and mPsARC responses were somewhat greater for those without a history of anti-TNF therapy than for those with prior anti-TNF therapy (ACR50: 52.3% versus 41.7%; mPsARC: 78.8% versus 71.2%).
Regulation (responses) of mPsARC
2) Confidence 0.01 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911911 Disease Relevance 0.25 Pain Relevance 0.38
At week 12, ACR50 and mPsARC responses were achieved by 10 and 13, respectively, of 18 patients with prior IFX therapy; by 11 and 18 of 30 patients with prior ETN therapy; and by four and 11 of 13 patients previously treated with both IFX and ETN (observed data).
Regulation (responses) of mPsARC associated with infliximab and etanercept
3) Confidence 0.01 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911911 Disease Relevance 0.27 Pain Relevance 0.48
Unadjusted logistic regression revealed that the likelihood of attaining an ACR50 response or mPsARC response did not considerably differ between patients without and those with prior anti-TNF therapy (Table 6).
Regulation (response) of mPsARC
4) Confidence 0.01 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911911 Disease Relevance 0.28 Pain Relevance 0.48

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox